Ivosidenib Market Report 2024 (Global Edition)

Global Ivosidenib Market Report 2024 Market Size Split by Patient Type (Adult, Pediatric), by End-User (Clinics, Homecare, Ambulatory Surgical Centers), by Distribution Channel (Hospital Pharmacies, R...

Ivosidenib Market Report Description

We have various report editions of Ivosidenib Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Competitive Landscape of the Ivosidenib Market

Key players deploy strategic initiatives such as product innovations, partnerships, and mergers. Companies prioritize R&D to introduce cutting-edge reagents, ensuring a competitive edge. Robust distribution networks and adherence to quality standards amplify market presence, fostering an environment where agility and innovation define industry leaders.

Top Companies Market Share in Ivosidenib Industry: (In no particular order of Rank)

• Agios Pharmaceuticals
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

In terms of revenue, the North American Ivosidenib Market share was 40% of the total market

According to Cognitive Market Research, North America dominated the market in 2024 and accounted for around 40% of the global revenue. Growing awareness and diagnosis of FLT3-mutated Acute Myeloid Leukemia (AML) are driving growth in the ivosidenib market in North America. Approximately 25–30% of AML cases have FLT3 mutations. Hence, ivosidenib's role as a targeted medication targets a sizable genetic population. The growing need for ivosidenib in North America is partly attributed to the region's focus on precision medicine and better treatment alternatives.

The Europe region is witnessing an increase in the sales of reagents. As more people in the region realize how important Ivosidenib is for treating FLT3-mutated Acute Myeloid Leukemia (AML), the market for the drug is expanding in Europe. The demand for Ivosidenib is driven by the growing recognition and diagnosis of FLT3 mutations, which account for many AML cases. Ivosidenib's market in Europe is growing due to the use of precision medicine and the accessibility of targeted medicines.

The current report Scope analyzes Ivosidenib Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Ivosidenib Market

According to Cognitive Market Research, the global Ivosidenib market size was estimated at USD 18.5Million out of which North America held the major market of more than 40% of the global revenue with a market size of USD 7.40 million in 2024 and will grow at a compound annual growth rate (CAGR) of 2.4% from 2024 to 2031. North America's market for ivosidenib is expanding due to the region's focus on precision medicine and better treatment choices for Acute Myeloid Leukemia (AML), with a specific focus on FLT3-mutated cases. About 25–30% of AML cases include FLT3 mutations, which is what is fueling the demand for Ivosidenib. Due to the healthcare industry's recognition of Ivosidenib's effectiveness, hospitals and pharmacies, among others, have a significant impact on its expansion. The drug's growing popularity and significance in offering patients within this particular genetic subtype of AML focused and efficient treatment is highlighted by the prescription of precise quantities, such 60 or 30 pills. The market's growth is indicative of North America's dedication to improving oncology care via targeted therapeutics and precision medicine.

• According to Cognitive Market Research, the US had a major share in the Ivosidenib market with a market size of USD 5.84 million in 2024 and is projected to grow at a CAGR of 2.2% during the forecast period. The demand is amplified by the investing in healthcare innovations. 
• The Canada Ivosidenib market had a market share of USD 0.89 million in 2024 and is projected to grow at a CAGR of 3.2% during the forecast period. Canada's rising genetic testing.
• The Mexico Ivosidenib market is projected to witness growth at a CAGR of 2.9% during the forecast period with a market size of USD 0.67 million in 2024.

Europe Ivosidenib Market

According to Cognitive Market Research, with a market value of USD 18.5 million in 2024, and projected to expand at a compound annual growth rate (CAGR) of 2.7% from 2024 to 2031. Europe accounted for a share of over 30% of the global Ivosidenib market size of USD 5.55 million. Europe's market for isoniazid is expanding significantly as a result of the region realizing how important this drug is for treating AML (acute myeloid leukemia) with FLT3 mutations. A significant proportion of AML cases have FLT3 mutations, which is one factor driving up the need for Ivosidenib. This targeted therapy is being actively adopted by European pharmacies and hospitals, as seen by prescriptions written for sets of pills, such as thirty or sixty. This emphasizes the usefulness and applicability of isosidenib in the European healthcare system, which is consistent with the continent's dedication to precision medicine and better treatment alternatives for patients with AML. The market's growth in Europe is indicative of a trend in the right direction—that is, the development of tailored therapies for certain genetic subgroups within the AML population.

• The United Kingdom Ivosidenib market had a market share of USD 0.93 million in 2024 and is projected to grow at a CAGR of 3.5% during the forecast period. In the UK, Ivosidenib sales witness an upswing due to the expanding healthcare infrastructure. 
• The France Ivosidenib market is projected to witness growth at a CAGR of 1.9% during the forecast period with a market size of USD 0.51 million in 2024.
• According to Cognitive Market Research, the Germany Ivosidenib market size was valued at USD 1.10 million in 2024 and is projected to grow at a CAGR of 2.9% during the forecast period. In Germany, Ivosidenib sales surge due to the an increase in the number of AML cases. 
• The Italy Ivosidenib market is projected to witness growth at a CAGR of 2.1% during the forecast period with a market size of USD 0.48 million in 2024.
• The Russia Ivosidenib market is projected to witness growth at a CAGR of 1.7% during the forecast period with a market size of USD 0.86 million in 2024.
• The Spain Ivosidenib market is projected to witness growth at a CAGR of 1.8% during the forecast period with a market size of USD 0.46 million in 2024.
• The Luxembourg Ivosidenib market is projected to witness growth at a CAGR of 2.8% during the forecast period with a market size of USD 0.17 million in 2024.
• The Portugal Ivosidenib market is projected to witness growth at a CAGR of 2.5% during the forecast period with a market size of USD 0.12 million in 2024.
• The Greece Ivosidenib market is projected to witness growth at a CAGR of 3.0% during the forecast period with a market size of USD 0.07 million in 2024.
• Rest of Europe Ivosidenib market is projected to witness growth at a CAGR of 1.4% during the forecast period with a market size of USD 0.86 million in 2024.

Asia Pacific Ivosidenib Market

According to Cognitive Market Research, the global Ivosidenib market size was estimated at USD 18.5Million out of which Asia Pacific held the market of around 23% of the global revenue with a market size of USD 4.26 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.2% from 2024 to 2031. Asia Pacific's market for isoniazid is expanding significantly as more people in the area become aware of the medication's effectiveness in treating FLT3-mutated acute myeloid leukemia (AML). Ivosidenib demand is rising in Asia Pacific as a result of the discovery that FLT3 mutations are present in a sizable fraction of AML cases. Prescriptions for particular amounts, such as 60 or 30 pills, indicate that healthcare providers, such as hospitals and pharmacies, are actively promoting the market's growth. This highlights the growing significance of Ivosidenib in delivering tailored and efficient treatment in the context of the local healthcare system. The expansion of the market in Asia Pacific highlights a favorable trend toward customized treatments and precision medicine, which cater to the distinct genetic traits of AML patients in this region.

• According to Cognitive Market Research, the China Ivosidenib market size was valued at USD 1.91 million in 2024 and is projected to grow at a CAGR of 5.7% during the forecast period. Ivosidenib sales surge in China due to the easy access to cutting-edge medical facilities.
• The Japan Ivosidenib market is projected to witness growth at a CAGR of 4.7% during the forecast period with a market size of USD 0.59 million in 2024.
• The India Ivosidenib market had a market share of USD 0.51 million in 2024 and is projected to grow at a CAGR of 8.0% during the forecast period. The demand is augmented by India's increasing nation's expanding precision medicine awareness.
• The South Korea Ivosidenib market is projected to witness growth at a CAGR of 5.3% during the forecast period with a market size of USD 0.43 million in 2024.
• The Australia Ivosidenib market is projected to witness growth at a CAGR of 5.9% during the forecast period with a market size of USD 0.22 million in 2024.
• The South East Asia Ivosidenib market is projected to witness growth at a CAGR of 7.2% during the forecast period with a market size of USD 0.29 million in 2024.
• The Rest of Asia Pacific Ivosidenib market is projected to witness growth at a CAGR of 6.0% during the forecast period with a market size of USD 0.30 million in 2024.

South America Ivosidenib Market

According to Cognitive Market Research, the global Ivosidenib market size was estimated at USD 18.5Million out of which Latin America market of more than 5% of the global revenue with a market size of USD 0.93 million in 2024 and will grow at a compound annual growth rate (CAGR) of 3.6% from 2024 to 2031. Latin America's market for isoniazid is expanding as a result of the region's growing understanding of the drug's importance in treating FLT3-mutated acute myeloid leukemia (AML). A significant portion of AML cases have FLT3 mutations, which has led to an increase in the demand for Ivosidenib. Hospitals and pharmacies in Latin America are enthusiastically implementing this targeted therapy, as seen by prescriptions written for sets of 60 or 30 tablets. This highlights the increasing significance of Ivosidenib in delivering accurate and efficient treatment in the healthcare system of Latin America. The market's growth in Latin America is indicative of a trend in the right direction—the advancement of precision medicine and the provision of specialized treatment choices for patients with AML in this area.

• According to Cognitive Market Research, the Brazil Ivosidenib market size was valued at USD 0.40 million in 2024 and is projected to grow at a CAGR of 4.2% during the forecast period. Ivosidenib sales flourish in Brazil due to the emphasis on precision medicine.
• The Argentina Ivosidenib market had a market share of USD 0.16 million in 2024 and is projected to grow at a CAGR of 4.5% during the forecast period. The demand is augmented by Argentina's high incidence of Acute Myeloid Leukemia (AML) cases.
• The Colombia Ivosidenib market is projected to witness growth at a CAGR of 3.4% during the forecast period with a market size of USD 0.08 million in 2024.
• The Peru Ivosidenib market is projected to witness growth at a CAGR of 3.8% during the forecast period with a market size of USD 0.08 million in 2024.
• The Chile Ivosidenib market is projected to witness growth at a CAGR of 3.9% during the forecast period with a market size of USD 0.07 million in 2024.
• The Rest of Latin America Ivosidenib market is projected to witness growth at a CAGR of 2.7% during the forecast period with a market size of USD 0.15 million in 2024.

Middle East and Africa Ivosidenib Market

According to Cognitive Market Research, the global Ivosidenib market size was estimated at USD 18.5Million out of which Middle East and Africa held the major market of around 2% of the global revenue with a market size of USD 0.37  million in 2024 and will grow at a compound annual growth rate (CAGR) of 3.9% from 2024 to 2031. The Middle East and Africa Ivosidenib market is starting to take off as a result of the region's growing recognition of the drug's importance in treating FLT3-mutated Acute Myeloid Leukemia (AML). A significant percentage of AML cases have FLT3 mutations, which has led to an increase in the demand for Ivosidenib. Prescriptions for sets of 60 or 30 tablets indicate that healthcare professionals in the Middle East and Africa, including hospitals and pharmacies, are gradually implementing this targeted medication. The progressive use of ivosidenib highlights the area's changing precision medicine strategy, providing customized treatment choices for AML patients with unique genetic traits and keeping pace with worldwide advances in oncology care.

• According to Cognitive Market Research, the GCC Countries Ivosidenib market size was valued at USD 0.16 million in 2024 and is projected to grow at a CAGR of 4.7% during the forecast period. Ivosidenib sales flourish in the GCC Countries due to the nation's sophisticated healthcare system.
• The Egypt Ivosidenib market is projected to witness growth at a CAGR of 4.2% during the forecast period with a market size of USD 0.04 million in 2024.
• The South Africa Ivosidenib market is projected to witness growth at a CAGR of 4.9% during the forecast period with a market size of USD 0.06 million in 2024. Ivosidenib sales flourish in the South Africa due to the active R&D.
• The Turkey Ivosidenib market is projected to witness growth at a CAGR of 3.4% during the forecast period with a market size of USD 0.03 million in 2024.
• The Nigeria Ivosidenib market is projected to witness growth at a CAGR of 3.0% during the forecast period with a market size of USD 0.04 million in 2024.
• The Rest of MEA Ivosidenib market is projected to witness growth at a CAGR of 2.9% during the forecast period with a market size of USD 0.04 million in 2024.

Ivosidenib Market Analysis

Ivosidenib Patient Type Segment Analysis

According to Cognitive Market Research, adults hold a prominent market share. Ivosidenib's effectiveness in treating relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) mutation is fueling the market's notable increase in the adult segment. Because adult patients with AML are the majority affected, there is a growing need for tailored treatments like Ivosidenib. Its ability to achieve remission and extend longevity in this patient population drives the rise of its market.

Pediatric is the fastest-growing category over the forecast period. Due to its potential efficacy in treating children patients with relapsed or refractory acute myeloid leukemia (AML) having an isocitrate dehydrogenase-1 (IDH1) mutation, the pediatric segment is emerging as a prominent driver of growth in the Ivosidenib market. Due to its capacity to induce remission and enhance survival rates in this particular patient population, ivosidenib is becoming more and more popular as a treatment for juvenile acute myeloid leukemia.

• Adult
• Pediatric

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Ivosidenib Industry. Request a Free Sample PDF!

Ivosidenib End-User Segment Analysis

According to Cognitive Market Research, Clinics held the major market share over the forecast period. The market for isosidenib in hospitals is expanding as medical professionals become more aware of its effectiveness in treating acute myeloid leukemia (AML) with FLT3 mutations. Because FLT3 mutations represent a sizable portion of AML cases, hospitals are essential to the Ivosidenib administration process, which fuels the market's growth. The market for Ivosidenib is driven by the emphasis on precision medicine and enhanced therapeutic alternatives in hospital settings.

Homecare is the fastest-growing category over the forecast period. The expanding market for Ivosidenib, since they are essential in providing this targeted treatment for Acute Myeloid Leukemia (AML) with FLT3 mutations. Because pharmacies are important access sources for patients, the growing demand for Ivosidenib is supported by their provision and facilitation of its distribution. The availability of targeted treatments and the focus on precision medicine are further factors propelling the expansion of pharmacy environments.

• Clinics
• Homecare
• Ambulatory Surgical Centers

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Ivosidenib Distribution Channel Segment Analysis

According to Cognitive Market Research, Hospital Pharmacies hold a prominent market share. Hospital pharmacies are a major source of ivosidenib for patients with relapsed or refractory acute myeloid leukemia (AML) who carry an isocitrate dehydrogenase-1 (IDH1) mutation. Hence, the market for this drug is expanding. Ivosidenib's market expansion in meeting unmet medical needs is facilitated by hospital pharmacies, which guarantee prompt availability of the medication and enable its administration as part of AML treatment protocols.

Retail Pharmacies are the fastest-growing category over the forecast period. Retail pharmacies are making Ivosidenib more accessible to patients with relapsed or refractory acute myeloid leukemia (AML) who have an isocitrate dehydrogenase-1 (IDH1) mutation, which is helping to drive the market for Ivosidenib. Retail pharmacies facilitate the expansion of the market for treating AML in community settings by stocking and dispensing Ivosidenib, a targeted medication which improves patient adherence and compliance.

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

LinkedIn

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Author's Conclusion